Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [978]

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival...

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology...

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical...

Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman...

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses ( Helena Ullgren, Rachel Powell, Irati Rodriguez-Matesanz and Elin Backman Stålnacke )

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact...

Helena Ullgren, Rachel Powell, Patrick Jahn and Elin Backman Stålnacke

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management ( Helena Ullgren, Rachel Powell, Patrick Jahn and Elin Backman Stålnacke )

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to...

Helena Ullgren, Elin Backman Stålnacke, Dr Pascale Tomasini and Gini Harrison

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care ( Helena Ullgren, Elin Backman Stålnacke, Dr Pascale Tomasini and Gini Harrison )

ASCO 2026: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2026: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

Yoga improves mood, fatigue, and insomnia in cancer survivors following...

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer ( Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA )

Low-dose pembrolizumab plus chemotherapy improves survival and expands access...

Dr Nandini Menon - Tata Memorial Centre, Mumbai, India

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC ( Dr Nandini Menon - Tata Memorial Centre, Mumbai, India )

More from ecancer